figitumumab Report issue

Biologics mAb Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Figitumumab is a monoclonal antibody targeting the insulin-like growth factor-1 receptor that was investigated for the treatment of various types of cancer, for example adrenocortical carcinoma and non-small cell lung cancer (NSCLC).   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

871 | cp-751 | cp751871 | cp 751871 | cp 751,871 | cp-751871 | cp-751,871 | cp751,871 | figitumumab

Organizations (6)

Research & Development (6)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (15)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (15)


 

Breast Neoplasms (Phase 2)

Carcinoma, Adenosquamous (Phase 3)

Carcinoma, Large Cell (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Squamous Cell (Phase 3)

Colorectal Neoplasms (Phase 2)

Head and Neck Neoplasms (Phase 2)

Healthy Volunteers (Phase 1)

Lung Neoplasms (Phase 1)

Multiple Myeloma (Phase 1)

Neoplasms (Phase 1)

Prostatic Neoplasms (Phase 2)

Sarcoma (Phase 1)

Sarcoma, Ewing (Phase 2)

Small Cell Lung Carcinoma (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 21
  • # of Trial Organizations: 6

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue